Jonathan F Anker

7PUBLICATIONS
67CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyInnate immunityDeep learningPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 01, 2026
Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer.

|Feb 26, 2026
A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.

Michelle A Tran, Byuri Angela Cho, Sudeh Izadmehr

|Jan 24, 2025
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer.

Matthew D Galsky, Mark Kockx, Juliette Roels

|Aug 22, 2023
Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer.

Jonathan Anker, Sumanta K Pal, Seunghee Kim-Schulze

|Aug 21, 2020
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.

R Vatapalli, V Sagar, Y Rodriguez

|Mar 03, 2019
Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma.

Young Kwang Chae, Jonathan F Anker, Michael S Oh

Pageof 2

Frequent Collaborators

3 joint publications

Matthew D Galsky

2 joint publications

Romain Banchereau

2 joint publications

Saurabh Gupta

2 joint publications

Sanjeev Mariathasan